Canaccord Genuity analyst Caitlin Cronin has maintained their neutral stance on ZBH stock, giving a Hold rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Caitlin Cronin’s rating is based on several factors influencing Zimmer Biomet Holdings’ current performance and future potential. The company has shown modest improvements in its financial results, notably with high single-digit growth in certain areas, but its U.S. knee performance still lags behind competitors like Striker. The resolution of ERP challenges marks progress, yet the associated headwinds have impacted sales.
With a focus on long-term goals, Zimmer Biomet has outlined a strategic four-point plan aimed at enhancing its operations, including new product launches and a proposed acquisition in the foot and ankle space. Although these initiatives could drive future growth, the conservative guidance and the need for further clarity in execution contribute to the Hold rating. The acquisition of Paragon 28 is expected to be initially dilutive but offers potential for growth, reinforcing the decision to maintain a cautious stance until more concrete results are observed.
In another report released today, Roth MKM also maintained a Hold rating on the stock with a $129.00 price target.
ZBH’s price has also changed slightly for the past six months – from $109.570 to $102.690, which is a -6.28% drop .